Oncology Medical News

Become a Member Today!
Register

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. Recommendations on the use of 18F-FDG PET in oncology

3. Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials

4. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer

5. Sentinel node biopsy is important in mastectomy for ductal carcinoma in situ

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Loss of SNF5 expression correlates with poor patient survival in melanoma
Clinical Cancer Research, 10/12/09

Lin H et al. – Our data indicate that SNF5 may be an important marker for human melanoma progression and prognosis as well as a potential therapeutic target.

Methods

Using tissue microarry and immunohistochemistry, SNF5 staining in 51 dysplastic nevi, 88 primary melanomas, and 48 metastatic melanomas evaluated
Studied chemosensitivity of melanoma cells with reduced SNF5 expression by siRNA using cell survival and apoptosis assays

Results

SNF5 expression reduced in metastatic melanoma compared with dysplastic nevi , in advanced primary melanoma (Clark's level V) compared with low risk Clark's level II melanoma , and in melanoma at sun-exposed sites compared with sun-protected sites
Strong correlation between negative SNF5 expression and worse 5-year survival in melanoma patients
Multivariate Cox regression analysis revealed negative SNF5 expression is independent prognostic factor to predict patient outcome in primary melanomas
Knockdown of SNF5 in melanoma cell lines resulted in significant chemoresistance

<< Previous
Young adults with acute lymphoblastic leukemia have an excellent...

Next >>
New lesions detected by single nucleotide polymorphism...